" class="no-js "lang="en-US"> OPEN Health Acquires Medical Communications Agency Spirit - Medtech Alert
Wednesday, February 08, 2023

OPEN Health Acquires Medical Communications Agency Spirit

OPEN Health has today announced the acquisition of North West UK-based medical communications agency Spirit. Integrating the Spirit business with the OPEN Health Group further strengthens our ability to offer our global Medical Affairs audiences a broad range of services, including high-quality scientific communications.

In terms of scale, the acquisition means that OPEN Health now consists of >850 people in 15 locations across 6 different countries, namely the USA, the UK, the NetherlandsGermanyIndia, and China.

Iona Fleming, Managing Director of Spirit, said, “Over the past 15 years, we have proudly grown Spirit to an 80-person Medical Affairs agency – delivering a broad range of scientific communications globally. In joining OPEN Health, we are significantly expanding our geographical reach and will be able to provide a wider range of integrated services to our Medical Affairs and HEOR clients. We very much look forward to working with the OPEN Health management and Amulet teams to contribute to the long-term growth of OPEN Health.”

Rob Barker, Chief Executive Officer at OPEN Health, commented, “We are delighted to welcome Spirit into the OPEN Health family. This strategic acquisition will enhance our global Medical Affairs resources, further supporting our unique offerings and opportunities for innovation to support industry change and growth.”

OPEN Health is a portfolio company of Amulet Capital Partners LP, a US-based private equity firm focused exclusively on the healthcare sector. 

People In This Post

Companies In This Post

  1. Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer Read more
  2. Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. Read more
  3. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth Read more
  4. Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer Read more
  5. TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials Read more